Infusion Laboratory: Protocol 3 (Risperidone) - 4

National Institute on Drug Abuse (NIDA)13 enrolled

Overview

The purpose of this study is to evaluate clinical safety issues pertaining to risperidone, to cocaine and to its interaction, and to determine how pretreatment with risperidone modifies the subjective as well as physiological effects of cocaine.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Cocaine-Related Disorders

Interventions

RisperidoneDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Locations (1)

Friends Research Institute

Los Angeles, California, United States

Outcomes

Primary Outcomes

Evidence of change in neurotoxicity based on chore

Degree of drug craving

History, incidence and amount of drug use

Type and severity of stimulant withdrawal symptoms

Characterization of study population

Population incidence of symptoms of depression, po

Frequency and intensity of drug use and sexual beh

Evidence of change in subjective responses to coca

Clinical physiological response to cocaine challen

Degree to which study medication influences change

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.